Joystiq has you covered with all things Metal Gear Solid 4!

AOL Money & Finance

Option Update: Genentech calls active on drug test faiure

Posted Apr 29th 2008 3:25PM by Paul Foster
Filed under: Genentech Inc (DNA), Options

Genentech Inc. (NYSE: DNA) is recently down $4.87 to $69.30.

DNA and Biogen Idec Inc. (NYSE: BIIB) announced that the phase three EXPLORER study evaluating Rituzan in Systemic Lupus Erythematosus (SLE) failed to meet its primary endpoint.

DNA call option volume of 31,631 contracts compares to put volume of 18,340 contracts. DNA May option implied volatility is at 27 and June is at 30; near its 26-week average according to Track Data, suggesting non-directional price movement.

Options Update is provided by Stock Specialist Paul Foster of theflyonthewall.com.

Tags: BIIB, DNA, Rituzan

  • Permalink
  • Email this
  • Comments [0]

Related Posts

Add your comments

Please keep your comments relevant to this blog entry. Email addresses are never displayed, but they are required to confirm your comments.

When you enter your name and email address, you'll be sent a link to confirm your comment, and a password. To leave another comment, just use that password.

To create a live link, simply type the URL (including http://) or email address and we will make it a live link for you. You can put up to 3 URLs in your comments. Line breaks and paragraphs are automatically converted — no need to use <p> or <br> tags.

New Users

Current Users

Symbol Lookup
IndexesChangePrice
DJIA+73.0311,288.54
NASDAQ-6.082,245.38
S&P 500+1.381,262.90

Last updated: July 04, 2008: 06:46 PM

BloggingStocks Exclusives

Hot Stocks

BloggingStocks Featured Video

TheFlyOnTheWall.com Headlines

WalletPop Headlines

AOL Business News

Latest from BloggingBuyouts

Sponsored Links

Most Commented On (14 days)

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

  • My Portfolio
  • Create a New Portfolio

Weblogs, Inc. Network